secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2022-05-11T23:59:59+00:00
Accession:  0000950170-22-009148
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surrozen reports Q1 2022 results; Phase 1 trials on track for Q3
----------------------------------------------------------------

- Q1 financial results announced; no specific revenue or loss figures in the press release excerpt.
- On track to initiate Phase 1 trials for SZN-1326 (ulcerative colitis) and SZN-043 (alcoholic hepatitis) in Q3 2022.
- Presented preclinical data for SZN-413 (retinal vascular diseases) at ARVO showing Wnt activation and vessel regrowth.
- Preclinical data for lacrimal gland and lung Wnt modulation highlighted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000095017022009148/0000950170-22-009148-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000095017022009148/srzn-20220511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-009148

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer